Form 4: Beta Bionics Director Acquires Stock Options

A Beta Bionics director, Adam Lezack, acquired stock options for 9,137 shares of common stock.

Summary

• Adam Lezack, a director at Beta Bionics, acquired stock options for 9,137 shares of common stock on January 31, 2025.
• The options have an exercise price of $5.10 per share.
• The options vest in 36 equal monthly installments starting from December 12, 2023.
• The options expire on December 11, 2033.
• The shares underlying the options were converted from Class B Common Stock to Common Stock prior to the company's initial public offering.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it indicates alignment of interests between management and shareholders. The sentiment is neutral to slightly positive.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders acquire or dispose of company securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, particularly in the technology and biotech sectors.
• The vesting schedule of 36 months is also a typical vesting period for such grants.
• The exercise price of $5.10 is specific to Beta Bionics and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The stock option grant could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, director, insider trading, beneficial ownership, Beta Bionics, BBNX